share_log

Morgan Stanley Downgrades Lyell Immunopharma to Equal-Weight, Lowers Price Target to $7

Morgan Stanley Downgrades Lyell Immunopharma to Equal-Weight, Lowers Price Target to $7

摩根士丹利將Lyell Immunopharma的評級下調至同等權重,將目標股價下調至7美元
Benzinga Real-time News ·  2022/11/14 06:22

Morgan Stanley analyst Matthew Harrison downgrades Lyell Immunopharma (NASDAQ:LYEL) from Overweight to Equal-Weight and lowers the price target from $15 to $7.

摩根士丹利分析師馬修·哈里森將萊爾免疫公司(納斯達克:LYEL)的評級從增持下調至持平,並將目標價從15美元下調至7美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論